Helen Evans, Deputy CEO

Challenges and Opportunities in Vaccines

and Global Immunisation

CSIS conference on the strategic power of vaccines Washington DC, 9 December 2011

Helen Evans – CSIS Conference

9 December 2011

Over 19 million children still unimmunised

Global number of under-five children unimmunised with 3 doses of DTP

Helen Evans – CSIS Conference

9 December 2011

Taking stock: the immunisation gap

136 million surviving newborns in 2010:

Source: Johns Hopkins Bloomberg School of Public Health;

UN,DESA, Population Division;

WHO/UNICEF

Helen Evans – CSIS Conference

9 December 2011

Synergies and shared learnings

Polio

eradication

Traditional

vaccines

Regional

vaccines

New

vaccines

Measles

elimination R&D: vaccine

improvements

R&D: future

vaccines

The immunisation landscape

Pneumococcal vaccine introductions:

introduced, approved and forecast

16

5

16

2 1

13 16

21

2 3

0

10

20

30

2009 2010 2011 2012 2013 2014 2015

number of

countries per

year

Forecast

Introduced

Approved

Pakistan

Madagascar

Ghana Uganda

Georgia

Moldova

Armenia Azerbaijan

Sudan

Zimbabwe Mozambique

Angola

Tanzania

Zambia

Niger Senegal

Bolivia

Sao Tome

Djibouti

Kiribati.

Gambia

Mali

Sierra Leone

Burundi

Benin

CAR Ethiopia

Guyana

Honduras

Nicaragua

Rwanda

Yemen

Kenya

Malawi

Cameroon Democratic

Republic of

the Congo

Helen Evans – CSIS Conference

9 December 2011

Rotavirus vaccine introductions: introduced,

approved and forecast

8 8

14

3 1 1

8

22

7 4

0

10

20

30

2009 2010 2011 2012 2013 2014 2015

Number

of

Countries

per year

Forecast

Introduced

Approved

Bolivia

Guyana

Nicaragua

Honduras Sudan

Tanzania

Madagascar

Angola

Republic of

the Congo

Cameroon Ghana

Niger

Yemen

Georgia Moldova

Armenia

Ethiopia

Djibouti

Malawi

Rwanda

Burundi

Source: Demand forecast v 4.0 Helen Evans – CSIS Conference

9 December 2011

Helen Evans – CSIS Conference

9 December 2011

Increased competition reduces vaccine price

Number of manufacturers and price decline of pentavalent vaccine

Source: UNICEF Supply Division, 2011

Helen Evans – CSIS Conference

9 December 2011

Increased competition reduces vaccine price

Number of manufacturers and volume of supply of pentavalent vaccine

Source: UNICEF Supply Division, 2011

Helen Evans – CSIS Conference

9 December 2011

Leveraging the market: GAVI’s Market Shaping in action 2011+

Short Term

Price decreases

• Pentavalent price decreases to $1.75 from $3 two years ago

• 67% price reduction offer on rotavirus - $2.5/dose

• 67% price reduction offer on HPV - $5/dose

Medium Term

New entrants

• 3 potential new entrants for rotavirus, yielding a further 40% price reduction target

• New entrants for pneumo, yielding a further price reduction of approx. 40%

• Graduating country price commitments

Long Term

Innovation

• Foster incremental innovation for appropriate and affordable new and follow-on products

• Improvements in vaccine technology

National leadership - Pneumococcal vaccine

launch, Kenya, 14 February 2011

Photo: GAVI/2011/Riccardo Gangale

Helen Evans – CSIS Conference

9 December 2011

Helen Evans – CSIS Conference

9 December 2011

Current cervical cancer mortality

Source: Globocan 2008, International Agency for Research on Cancer.

Courtesy of Progress in Cervical Cancer Prevention:

The CCA Report Card, August 2011

Helen Evans – CSIS Conference

9 December 2011

Introduction of HPV vaccine

Source: Courtesy of Progress in Cervical Cancer Prevention:

The CCA Report Card, August 2011

Status: July 2011